Gómez-Banoy, Nicolás http://orcid.org/0000-0002-3552-1768
Guseh, J. Sawalla http://orcid.org/0000-0003-0992-5635
Li, Ge
Rubio-Navarro, Alfonso http://orcid.org/0000-0001-5677-3123
Chen, Tong
Poirier, BreAnne
Putzel, Gregory
Rosselot, Carolina
Pabón, Maria A.
Camporez, João Paulo
Bhambhani, Vijeta
Hwang, Shih-Jen
Yao, Chen http://orcid.org/0000-0002-3944-7788
Perry, Rachel J.
Mukherjee, Sushmita
Larson, Martin G.
Levy, Daniel
Dow, Lukas E.
Shulman, Gerald I. http://orcid.org/0000-0003-1529-5668
Dephoure, Noah
Garcia-Ocana, Adolfo
Hao, Mingming http://orcid.org/0000-0003-4677-5111
Spiegelman, Bruce M.
Ho, Jennifer E. http://orcid.org/0000-0002-7987-4768
Lo, James C. http://orcid.org/0000-0003-0244-1670
Funding for this research was provided by:
Cornell University | Weill Cornell Medical College (Department of Medicine Seed Grant for Innovative Research)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK097303, DK111762, DK121844, DK-059635, DK116774, DK114793, DK045735)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL140224, HL134893)
American Diabetes Association (1-18-PMF-032)
Massachusetts General Hospital (HL007208, Physician Scientist Development Program)
Article History
Received: 3 October 2018
Accepted: 12 September 2019
First Online: 7 November 2019
Competing interests
: Cornell University has filed a provisional patent application that covers the use of DUSP26 inhibitors for the treatment of type 2 diabetes. (US patent application no. 62/740744; N.G.-B. and J.C.L.). V.B. is currently an employee of Fractyl Laboratories Inc. and all analyses were conducted during employment at Massachusetts General Hospital.